Medical Translation

Medical Device Translation for ANVISA Registration in Brazil

Nov 19, 20265 min read
Medical Device Translation for ANVISA Registration in Brazil

A European medical device manufacturer looking to sell in Brazil must submit its technical dossier to ANVISA (Agência Nacional de Vigilância Sanitária) in Brazilian Portuguese. Labelling, instructions for use, clinical evaluation reports and declarations of conformity all have to reach the agency without terminological ambiguity, because a poorly chosen term can trigger a technical query that delays the process by months.

ANVISA classifies devices into four risk classes (I, II, III and IV) and requires documentation proportional to that classification. For classes III and IV, the dossier typically includes a technical product report, clinical performance evidence, instructions for use (IFU) and complete labelling. All of this documentation, if originally produced in another language, needs translation into Brazilian Portuguese before submission.

What ANVISA requires in translated documentation

The agency does not accept literal translations produced without knowledge of Brazilian regulatory terminology. Terms such as "instructions for use", "intended purpose" or "essential requirements" have established technical equivalents in Brazilian Portuguese, used by ANVISA itself in its resolutions (RDC). Using terminology that departs from the official usage is a common error that generates requests for clarification.

The documents most frequently required are:

  • Labelling and instructions for use (IFU), which must follow the format and mandatory statements set out in the applicable RDC for the device type
  • Clinical evaluation report, with consistent medical terminology between the original document and the translated version
  • Good Manufacturing Practice (GMP) certificate or foreign equivalent, whose translation must accurately reflect the scope of the certification
  • Declaration of conformity and supporting technical documentation, including specifications, drawings and test reports

Terminological consistency across documents matters as much as the accuracy of any single sentence. If the manual calls a component a "pressure sensor" and the technical report calls it a "pressure transducer", ANVISA may read that as a technical inconsistency rather than a stylistic variation.

How the Brazilian dossier differs from the EU MDR dossier

Anyone who has already prepared technical documentation for the EU Medical Device Regulation (MDR) tends to assume that translating for ANVISA is simply a matter of language. It is not. Document structure, required labelling formats, and even how clinical data is presented differ between the two regulatory systems.

Teams managing both dossiers in parallel may want to review the specific requirements on the European side in our piece on medical device documentation translation for MDR compliance, which details the documentary requirements that apply there.

ANVISA often also requires documentation from clinical trials conducted outside Brazil, translated and localised with the same terminological rigour demanded by the originating regulatory authorities. The criteria applicable to that type of protocol are covered in our article on translating clinical trial protocols for regulatory submission.

Mistakes that delay registration and how to avoid them

The most common mistakes are not grammatical, they are technical. A clinical evaluation report with inconsistencies between the number of patients reported in the summary and in the body of the text invites a technical query. An IFU translated without respecting standardised symbol formatting (ISO 15223-1) does too.

Another frequent mistake is treating pharmaceutical translation and medical device translation as interchangeable. They share medical terminology, but regulatory requirements, labelling formats and risk classifications differ. This also applies to drug labelling, where the specific requirements are described in our article on drug labelling translation.

A third mistake is underestimating document volume. Class III and IV dossiers can run to hundreds of pages across technical reports, clinical annexes and specifications. Without centralised terminology management, glossary and translation memory, consistency between documents delivered at different stages of the process degrades.

How M21Global handles this type of dossier

For documentation intended for regulatory submission, such as ANVISA dossiers, M21Global recommends the Estratégica tier: translation, review by a second linguist, and quality control within the audited ISO 17100 workflow, with terminology management dedicated to the project. It is the right level of assurance when a terminological error can mean months of delay in registering a device.

The team works with glossaries specific to each device class and maintains consistency across labelling, IFU and technical reports throughout the full dossier. Request a quote for your medical device documentation through our pharmaceutical translation service and receive a proposal within three business hours.

Request a free medical translation quote

Frequently Asked Questions

Does translation for ANVISA need to be certified?

ANVISA requires technical rigour and terminological accuracy, not a sworn or certified translation in the legal sense. What matters is the quality and technical consistency of the Brazilian Portuguese text, with review appropriate to the dossier's criticality.

Which medical device documents need translation for ANVISA?

Typically labelling, instructions for use (IFU), clinical evaluation report, good manufacturing practice certificate and declaration of conformity, among other supporting technical documents, depending on the device's risk class.

What is the difference between the ANVISA dossier and the EU MDR dossier?

The two regulatory systems require different document structures, labelling formats and presentation of clinical data. Translating for ANVISA is not simply a linguistic conversion of the MDR dossier, it needs adaptation to Brazil-specific requirements.

What happens if the translation has terminological inconsistencies?

ANVISA can issue a technical query requesting clarification or correction, which delays the registration process, sometimes by several months.

Need Professional Translation?

Request a free, no-obligation quote for your translation project.

Request Quote